Bristol Myers Squibb (NYSE: BMY) strengthens Camzyos growth case with positive adolescent SCOUT-HCM data
Read More Pharma Industry News AAVantgarde clears key execution hurdle as LUCE-1 Phase 1/2 study of AAVB-081 completes enrollment Find out how AAVantgarde Bio’s LUCE-1 enrollment milestone reshapes the gene therapy landscape for Usher syndrome type B retinitis pigmentosa. bySoujanya RaviJanuary 18, 2026